TWI381836B - Ａｋｔ活性抑制劑 - Google Patents

Ａｋｔ活性抑制劑 Download PDF

Info

Publication number
TWI381836B
TWI381836B TW097104414A TW97104414A TWI381836B TW I381836 B TWI381836 B TW I381836B TW 097104414 A TW097104414 A TW 097104414A TW 97104414 A TW97104414 A TW 97104414A TW I381836 B TWI381836 B TW I381836B
Authority
TW
Taiwan
Prior art keywords
methyl
cancer
amino
ethyl
mmol
Prior art date
Application number
TW097104414A
Other languages
English (en)
Chinese (zh)
Other versions
TW200845964A (en
Inventor
Mark Andrew Seefeld
Meagan B Rouse
Dirk A Heerding
Simon Peace
Dennis S Yamashita
Kenneth C Mcnulty
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39682107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI381836(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of TW200845964A publication Critical patent/TW200845964A/zh
Application granted granted Critical
Publication of TWI381836B publication Critical patent/TWI381836B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW097104414A 2007-02-07 2008-02-05 Ａｋｔ活性抑制劑 TWI381836B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88858607P 2007-02-07 2007-02-07

Publications (2)

Publication Number Publication Date
TW200845964A TW200845964A (en) 2008-12-01
TWI381836B true TWI381836B (zh) 2013-01-11

Family

ID=39682107

Family Applications (2)

Application Number Title Priority Date Filing Date
TW097104414A TWI381836B (zh) 2007-02-07 2008-02-05 Ａｋｔ活性抑制劑
TW100116246A TWI507194B (zh) 2007-02-07 2008-02-05 Ａｋｔ活性抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW100116246A TWI507194B (zh) 2007-02-07 2008-02-05 Ａｋｔ活性抑制劑

Country Status (35)

Country Link
US (7) US8410158B2 (fr)
EP (1) EP2117523B1 (fr)
JP (3) JP4723677B2 (fr)
KR (3) KR20140140570A (fr)
CN (1) CN101646427B (fr)
AR (1) AR066184A1 (fr)
AU (1) AU2008213694B2 (fr)
BR (1) BRPI0807146B8 (fr)
CA (1) CA2678255C (fr)
CL (1) CL2008000348A1 (fr)
CO (1) CO6220930A2 (fr)
CR (1) CR10995A (fr)
CY (1) CY1115535T1 (fr)
DK (1) DK2117523T3 (fr)
DO (1) DOP2009000196A (fr)
EA (1) EA018038B1 (fr)
ES (1) ES2501518T3 (fr)
HK (1) HK1132676A1 (fr)
HR (1) HRP20140790T1 (fr)
IL (1) IL200212A (fr)
JO (1) JO3134B1 (fr)
MA (1) MA31167B1 (fr)
MX (2) MX2009008550A (fr)
MY (1) MY164480A (fr)
NZ (1) NZ579177A (fr)
PE (1) PE20090058A1 (fr)
PL (1) PL2117523T3 (fr)
PT (1) PT2117523E (fr)
SG (1) SG193678A1 (fr)
SI (1) SI2117523T1 (fr)
TW (2) TWI381836B (fr)
UA (1) UA102992C2 (fr)
UY (1) UY30892A1 (fr)
WO (1) WO2008098104A1 (fr)
ZA (1) ZA200905363B (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
PE20120003A1 (es) * 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2393827B1 (fr) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Nouveaux promédicaments à base d'inhibiteurs cyp17 stéroïdiens/anti-androgènes
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
KR20120099219A (ko) * 2009-09-23 2012-09-07 글락소스미스클라인 엘엘씨 조합물
EP2480085B1 (fr) * 2009-09-23 2014-11-12 GlaxoSmithKline LLC Combinaison comprenant l'inhibiteur de MEK N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo- phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide et l'inhibiteur d'Akt N-{(1S)-2-amino-1-[(3-fluorophényl)-méthyl] éthyl}-5-chloro-4-(4-chloro-1-méthyl-1H-pyrazole-5-yl )-2-thiophène-carboxamide
MX2012004139A (es) * 2009-10-08 2012-09-07 Glaxosmithkline Llc Combinacion.
AU2010303364B2 (en) 2009-10-08 2013-09-19 Novartis Ag Combination
WO2011060380A1 (fr) * 2009-11-14 2011-05-19 The Regents Of The University Of California L'état de mutation de pik3ca et l'expression de sash1 prédisent la synergie entre le lapatinib et un inhibiteur d'akt dans le cancer du sein her2 positif
CA2794153C (fr) 2010-03-25 2018-01-02 Glaxosmithkline Llc Derives d'indoline substitue comme inhibiteurs de perk
EP2560966B1 (fr) 2010-03-30 2021-01-06 Verseon International Corporation Composés aromatiques multisubstitués utilisés comme inhibiteurs de la thrombine
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
EP2575460A4 (fr) * 2010-05-26 2013-10-16 Glaxosmithkline Llc Combinaison
WO2012021611A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2620428B1 (fr) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
PE20141044A1 (es) 2010-10-13 2014-09-07 Millennium Pharm Inc Heteroarilos y sus usos
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
KR20140053836A (ko) 2011-01-11 2014-05-08 글락소스미스클라인 엘엘씨 조합물
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184542A1 (en) 2011-01-19 2012-07-19 Kevin Anderson Pyrido pyrimidines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012177925A1 (fr) 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
WO2013096637A1 (fr) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
AR090795A1 (es) * 2012-04-24 2014-12-10 Glaxosmithkline Intellectual Property N 2 Ltd Metodo de tratamiento de las dermatosis sensibles a los esteroides, composicion farmaceutica
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
WO2014012081A2 (fr) 2012-07-13 2014-01-16 Ontorii, Inc. Contrôle chiral
WO2014049488A1 (fr) 2012-09-28 2014-04-03 Pfizer Inc. Composés de benzamide et hétérobenzamide
EP2909193B1 (fr) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Modulateurs de ror-gamma-t de type quinolinyle à liaison phényle
WO2014062658A1 (fr) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Modulateurs de ror-gamma-t de type quinolinyle à liaison méthylène
EP2909189B8 (fr) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Modulateurs de ror-gamma-t de type quinolinyle à liaison hétéroaryle
JP2015534986A (ja) * 2012-10-22 2015-12-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組合せ
AU2013352369B2 (en) 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
CA2897559A1 (fr) 2013-01-09 2014-07-17 Glaxosmithkline Intellectual Property (No.2) Limited Combinaison
WO2014134267A1 (fr) 2013-02-27 2014-09-04 Bristol-Myers Squibb Company Composés de carbazole utiles en tant qu'inhibiteurs de bromodomaine
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
EP2970141B1 (fr) * 2013-03-15 2020-02-26 Verseon Corporation Halogénopyrazoles en tant qu'inhibiteurs de la thrombine
LT2968297T (lt) 2013-03-15 2019-01-10 Verseon Corporation Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
BR112016002970A2 (pt) 2013-08-12 2017-09-12 Tokai Pharmaceuticals Inc biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
MX2016004265A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
AU2014330779A1 (en) * 2013-10-01 2016-04-07 Novartis Ag Combination
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
AU2014334616A1 (en) 2013-10-15 2016-04-28 Janssen Pharmaceutica Nv Quinolinyl modulators of RORyt
WO2015057206A1 (fr) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Modulateurs d'alcool secondaire de roryt de type quinolinyle
WO2015056180A1 (fr) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Dérivés d'indoline utilisés comme inhibiteurs de perk
PE20160844A1 (es) 2013-12-24 2016-09-03 Bristol Myers Squibb Co Compuestos triciclicos como agentes anticancerigenos
EP3095460A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
WO2015108047A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
CA2942204A1 (fr) * 2014-03-12 2015-09-17 Novartis Ag Combinaison comprenant un inhibiteur de btk et un inhibiteur d'atk
CN104926801B (zh) 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
RU2705800C2 (ru) 2014-06-06 2019-11-12 Рисерч Трайэнгл Инститьют Агонисты рецептора апелина (apj) и их применение
CA2960790A1 (fr) 2014-09-17 2016-03-24 Verseon Corporation Composes de pyridone substituee par pyrazolyl en tant qu'inhibiteurs de serine protease
WO2016059602A2 (fr) 2014-10-16 2016-04-21 Glaxo Group Limited Méthodes de traitement du cancer et compositions associées
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
EP3261639B1 (fr) 2015-02-27 2022-08-24 Verseon International Corporation Composés pyrazole substitués à utiliser en tant qu'inhibiteurs de sérine protéase
EP3380097A2 (fr) 2015-08-28 2018-10-03 Novartis AG Combinaison pharmaceutique comprenant (a) l'inhibiteur au pi3k isoforme-alpha spécifique alpelisib (byl719) et (b) un inhibiteur à akt, de préférence mk-2206, afuresertib ou uprosertib, et son utilisation dans le traitement/la prévention du cancer
WO2017098421A1 (fr) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Composés benzothiadiazine
MA43417A (fr) 2015-12-09 2018-10-17 Res Triangle Inst Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2017153952A1 (fr) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited Dérivés de 5-sulfamoyl-2-hydroxybenzamide
EP3473628B1 (fr) * 2016-06-16 2019-12-11 Harbin Zhenbao Pharmaceutical Co., Ltd. Composé dihydropyrazole azépine servant d'inhibiteur d'akt
US11926612B2 (en) * 2016-10-12 2024-03-12 Research Triangle Institute Heterocyclic apelin receptor (APJ) agonists and uses thereof
JP2020510618A (ja) 2016-12-01 2020-04-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌を処置する方法
CN107011377B (zh) * 2017-05-03 2019-02-26 南通书创药业科技有限公司 一种β-羰基磷酸酯的制备方法
KR20200024890A (ko) 2017-07-05 2020-03-09 노파르티스 아게 신규한 약학적 조성물
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (fr) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
WO2019114741A1 (fr) 2017-12-13 2019-06-20 南京明德新药研发股份有限公司 Sel servant d'inhibiteur d'akt et cristal de celui-ci
WO2020023340A1 (fr) 2018-07-23 2020-01-30 Signalrx Pharmaceuticals, Inc. Composés à molécule unique fournissant une inhibition multi-cible de btk et d'autres protéines et leurs méthodes d'utilisation
EP3866807A1 (fr) 2018-10-16 2021-08-25 F. Hoffmann-La Roche AG Utilisation d'inhibiteurs d'akt en ophtalmologie
EP3877511A1 (fr) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion de til utilisant des inhibiteurs de la voie akt
BR112021010353A2 (pt) 2018-11-30 2021-08-31 Glaxosmithkline Intellectual Property Development Limited Compostos úteis em terapia hiv
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
WO2021018941A1 (fr) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Méthodes de traitement du cancer
JP2022543679A (ja) 2019-08-08 2022-10-13 ラークナ・リミテッド 癌を処置する方法
WO2021191417A1 (fr) 2020-03-27 2021-09-30 Som Innovation Biotech, S.A. Composés destinés à être utilisés dans le traitement de synucléinopathies
CN111592531B (zh) * 2020-06-23 2023-08-15 上海鲲博玖瑞医药科技发展有限公司 福瑞塞替的制备方法
CN111620860B (zh) * 2020-06-23 2023-02-03 济南健丰化工有限公司 一种福瑞塞替的制备方法
WO2022069554A1 (fr) 2020-10-01 2022-04-07 Bayer Aktiengesellschaft Procédé de production de 4-bromofuran-2-carboxylates
WO2023174210A1 (fr) 2022-03-14 2023-09-21 Laekna Limited Traitement combiné pour le cancer
WO2023187037A1 (fr) 2022-03-31 2023-10-05 Astrazeneca Ab Inhibiteurs de tyrosine kinase du récepteur du facteur de croissance épidermique (egfr) en combinaison avec un inhibiteur d'akt pour le traitement du cancer
WO2023230541A1 (fr) 2022-05-27 2023-11-30 Viiv Healthcare Company Dérivés de pipérazine utiles dans le traitement du vih
WO2024083716A1 (fr) 2022-10-17 2024-04-25 Astrazeneca Ab Combinaisons d'un serd pour le traitement du cancer
WO2024100236A1 (fr) 2022-11-11 2024-05-16 Astrazeneca Ab Polythérapies pour le traitement du cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0712397B1 (fr) * 1993-08-06 1999-04-21 Smithkline Beecham Plc Derives amides employes comme antagonistes du recepteur 5ht1d
WO2006136837A2 (fr) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Composes pharmaceutiques

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1030415A (zh) 1987-02-20 1989-01-18 山之内制药株式会社 饱和的杂环碳酰胺衍生物和它的制备方法
ES2005163A6 (es) 1987-04-14 1989-03-01 Lilly S A E Un procedimiento para la produccion de derivados de tiofen-2-carboxamida.
EP0333427B1 (fr) 1988-03-16 1995-08-23 Smithkline Beecham Farmaceutici S.p.A. Dérivés d'hétérocycles
DE3810848A1 (de) 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
DE3927483A1 (de) 1989-08-19 1991-02-21 Boehringer Ingelheim Kg Neue substituierte heterocyclische fuenfringe, ihre herstellung und verwendung
DE3933573A1 (de) 1989-10-07 1991-04-18 Basf Ag Carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
CA2144762A1 (fr) 1992-10-14 1994-04-28 George D. Hartman Antagonistes des recepteurs du fibrinogene
WO1994010145A1 (fr) 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Ligands pour les sous-types de recepteurs de dopamine
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5668148A (en) * 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
ATE198593T1 (de) 1995-08-02 2001-01-15 Uriach & Cia Sa J Pyrimidonderivate mit antifungaler wirkung
WO1997008133A1 (fr) 1995-08-22 1997-03-06 Japan Tobacco Inc. Composes amide et leur utilisation
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
WO1997036898A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
AU716381B2 (en) 1996-04-03 2000-02-24 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036585A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
AU721952B2 (en) 1996-04-03 2000-07-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2250231A1 (fr) 1996-04-03 1997-10-09 Robert P. Gomez Inhibiteurs de la farnesyl-proteine transferase
WO1997036901A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de transferase de farnesyl-proteine
JP2001509131A (ja) 1996-04-03 2001-07-10 メルク エンド カンパニー インコーポレーテッド ファルネシルプロテイントランスフェラーゼの阻害剤
WO1997036890A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de transferase de farnesyl-proteine
CA2249665A1 (fr) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
AUPO163896A0 (en) 1996-08-14 1996-09-05 Resmed Limited Determination of respiratory airflow
AU6320998A (en) 1997-02-21 1998-09-09 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
US5998336A (en) 1997-02-26 1999-12-07 The Board Of Trustees Of The Leland Stanford Junior University Ceramic/metal and A15/metal superconducting composite materials exploiting the superconducting proximity effect and method of making the same
ATE334975T1 (de) 1997-05-30 2006-08-15 Takeda Pharmaceutical Sulfonamidderivate, ihre herstellung und verwendung
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AU1722899A (en) 1997-12-12 1999-07-05 Euro-Celtique S.A. Preparation of 3-substituted adenines
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AUPP433398A0 (en) 1998-06-25 1998-07-16 Australian National University, The Compounds and processes
US6192967B1 (en) 1998-10-19 2001-02-27 Sunny En Liung Huang Collapsible auto shade
US6130333A (en) 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
DE19904397A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
DE19904396A1 (de) 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
JP2000256358A (ja) 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
CA2368049A1 (fr) 1999-04-13 2000-10-19 Basf Aktiengesellschaft Ligands de recepteurs d'integrine
EP1181270A2 (fr) 1999-05-24 2002-02-27 Cor Therapeutics, Inc. Inhibiteurs du facteur xa
WO2000071508A2 (fr) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibiteurs du facteur xa
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CA2392576A1 (fr) 1999-11-24 2001-05-31 Lingyan Wang Inhibiteurs du facteur xa a base d'acides .beta.-amines, aspartiques et diaminopropioniques
TR200103147T1 (tr) 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2001056557A2 (fr) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions utiles comme inhibiteurs de erk
SK14082001A3 (sk) * 2000-02-05 2002-03-05 Vertex Pharmaceuticals Incorporated Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
GB0011098D0 (en) 2000-05-08 2000-06-28 Black James Foundation Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
EP1282418B1 (fr) * 2000-05-19 2005-08-17 Applied Research Systems ARS Holding N.V. Composes actifs sur le plan pharmaceutiques et procedes d'utilisation
US6589195B1 (en) * 2000-05-26 2003-07-08 Orthomerica Products, Inc. Modular adjustable prophylactic hip orthosis and adduction/abduction joint
WO2002000647A1 (fr) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Inhibiteurs du facteur xa a substitution heteroaryl-phenyle
AU2001277143A1 (en) 2000-07-24 2002-02-05 Davide Riccardo Grassetti Inhibition of mutagenic effects of carcinogens
GB0018758D0 (en) * 2000-07-31 2000-09-20 Smithkline Beecham Plc Novel use and compunds
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
ES2274005T3 (es) 2001-01-26 2007-05-16 Chugai Seiyaku Kabushiki Kaisha Inhibidores de malonyl-coa decarboxilasa usados como moduladores metabolicos.
EP1390353A1 (fr) 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Derives triazole inhibiteurs des kinases et leurs utilisations
DE10223912A1 (de) * 2001-06-28 2003-01-16 Merck Patent Gmbh TN- und STN-Flüssigkristallanzeigen
US20030015823A1 (en) * 2001-07-18 2003-01-23 Hydranautics Method for forming a thick section, thermoset, solid casting
AU2002321910A1 (en) 2001-08-03 2003-02-17 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
EP1423380B1 (fr) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Inhibiteurs de kinase derives du pyrazole et leurs utilisations
CA2458375A1 (fr) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Heteroaryl-7-aza¬2.2.1|bicycloheptanes substitues destines au traitement de maladies
ATE372114T1 (de) * 2001-09-27 2007-09-15 Applied Research Systems Verfahren zur erhöhung des testosteronspiegels
US6794252B2 (en) * 2001-09-28 2004-09-21 Texas Instruments Incorporated Method and system for forming dual work function gate electrodes in a semiconductor device
WO2003035619A1 (fr) 2001-10-25 2003-05-01 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
WO2003039529A1 (fr) 2001-11-07 2003-05-15 4Sc A.G. Agents antibacteriens selectifs
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
SG159380A1 (en) 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
US7335779B2 (en) 2002-03-08 2008-02-26 Quonova, Llc Modulation of pathogenicity
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0206861D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
EP1494997A4 (fr) 2002-04-05 2007-04-11 Merck & Co Inc Arylamides substituee
MXPA04010550A (es) 2002-04-26 2005-01-25 Pfizer Prod Inc Inhibidores de metaloproteinasa de pirimidina-2,4,6-triona.
JP2005529328A (ja) * 2002-06-05 2005-09-29 ファーマシア アンド アップジョン カンパニー 競合的結合１ｈｎｍｒ実験を用いたリガンドの同定方法
GB0216224D0 (en) * 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
CA2494114A1 (fr) * 2002-08-02 2004-02-12 Argenta Discovery Limited Acides substitues thienylhydroxamiques utilises en tant qu'inhibiteurs d'histone desacetylase
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的噁二唑
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US7166619B2 (en) 2002-08-14 2007-01-23 Ppd Discovery , Inc. Prenylation inhibitors and methods of their synthesis and use
DE60333762D1 (de) 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
DE10239443A1 (de) 2002-08-28 2004-03-11 Boehringer Ingelheim International Gmbh Blockiervorrichtung für ein Sperrspannwerk mit federbetätigtem Abtrieb
EP1398029A1 (fr) * 2002-09-10 2004-03-17 LION Bioscience AG Derivés de pyrazole,substitués en position 3 ayant une affinité envers le NR3B1 récepteur
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
AU2003297431A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
CA2515235A1 (fr) 2003-02-10 2004-08-19 Bayer Healthcare Ag Derives de bis(hetero)aryle carboxamide destines a etre utilises en tant qu'antagonistes de la pg12
WO2004072018A1 (fr) 2003-02-12 2004-08-26 Takeda Pharmaceutical Company Limited Derive d'amine
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
EP1599447A1 (fr) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands modulant des recepteurs du type lxr
US7517887B2 (en) 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
TW200512195A (en) 2003-04-21 2005-04-01 Elan Pharm Inc Benzamide 2-hydroxy-3-diaminoalkanes
JP4716996B2 (ja) * 2003-05-26 2011-07-06 武田薬品工業株式会社 スルホピロール
EP1638964B1 (fr) 2003-06-20 2011-07-27 Galderma Research & Development Nouveaux composes qui modulent les recepteurs de type ppar-gamma et utilisations de ceux-ci dans des compositions cosmetiques ou pharmaceutiques
DE10331305A1 (de) 2003-07-10 2005-02-17 Siemens Ag Kommunikationssystem, Peer-to-Peer-Nachrichten-Filter-Rechner und Verfahren zum Verarbeiten einer Peer-to-Peer-Nachricht
FR2857666B1 (fr) 2003-07-15 2005-08-26 Oreal Composition tinctoriale comprenant a titre de coupleur un derive du furane et nouveaux derives du furane
TWI376370B (en) 2003-07-23 2012-11-11 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
WO2005019200A2 (fr) 2003-08-14 2005-03-03 Icos Corporation Derives d'arylpiperidine utilises en tant qu'antagonistes d'integrine vla-1 et utilisations de ceux-ci
DE602004012578T2 (de) 2003-08-15 2008-12-11 Vertex Pharmaceuticals Inc., Cambridge Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
WO2005019182A1 (fr) 2003-08-20 2005-03-03 Bayer Healthcare Ag Derives de pyrazolylmethylbenzamide utilises comme antagonistes du recepteur p2xt
US20070004771A1 (en) 2003-10-06 2007-01-04 Glaxo Group Limited Preparation of 1,6,7-trisubstituted azabenzimidazoles as kinase inhibitors
WO2005037198A2 (fr) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
WO2005048953A2 (fr) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Derives d'amide utilises comme modulateurs de la kinase
CN102786482A (zh) 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
EP1706159B1 (fr) 2004-01-19 2013-06-26 Atul Kumar Système permettant de distendre des cavités corporelles par irrigation à écoulement continu
US20080293716A1 (en) 2004-01-30 2008-11-27 Smithkline Beecham Corporation Chemical Compounds
WO2005077345A1 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Composes pour le traitement de la maladie du reflux gastro-oesophagien
WO2005077373A2 (fr) 2004-02-03 2005-08-25 Astrazeneca Ab Nouveau traitement du reflux gastro-oesophagien pathologique ii
WO2005081954A2 (fr) 2004-02-25 2005-09-09 Wyeth Inhibiteurs de la proteine tyrosine phosphatase 1b
US20070211713A1 (en) * 2004-03-30 2007-09-13 Toshiharu Koshino Content relay server, content replay system, content relay method, and program using the same
AU2005228899A1 (en) * 2004-03-30 2005-10-13 Novartis Vaccines And Diagnostics, Inc. Substituted thiophene derivatives as anti-cancer agents
JP2008502595A (ja) 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
JP2005336172A (ja) 2004-04-26 2005-12-08 Japan Tobacco Inc 腎虚血再灌流障害治療又は予防薬
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
WO2005116001A1 (fr) * 2004-05-29 2005-12-08 7Tm Pharma A/S Acides thiazoleacetiques substitues en tant que ligands crth2
US20060135773A1 (en) 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
EP2325184A1 (fr) * 2004-06-30 2011-05-25 Vertex Pharmceuticals Incorporated Azaindoles utilés en tant qu'inhibiteurs des proteine kinases
US7671077B2 (en) * 2004-07-19 2010-03-02 Leu-Fen Hou Lin Neuroprotective small organic molecules, compositions and uses related thereto
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
US20060019968A1 (en) * 2004-07-24 2006-01-26 Laboratorios Dr. Esteve S.A. Use of compounds active on the sigma receptor for the treatment of neuropathic pain
US7269099B2 (en) 2004-07-30 2007-09-11 Bolt Technology Corporation Air gun
JP2006066488A (ja) * 2004-08-25 2006-03-09 Mitsubishi Electric Corp 半導体受光素子およびその製造方法
US7365385B2 (en) * 2004-08-30 2008-04-29 Micron Technology, Inc. DRAM layout with vertical FETs and method of formation
US20060043513A1 (en) * 2004-09-02 2006-03-02 Deok-Hoon Kim Method of making camera module in wafer level
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
US20060062453A1 (en) * 2004-09-23 2006-03-23 Sharp Laboratories Of America, Inc. Color highlighting document image processing
WO2006043518A1 (fr) 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. Médicament pour le traitement de maladies neurologiques
JP2006120339A (ja) 2004-10-19 2006-05-11 Matsushita Electric Ind Co Ltd 高周波加熱電源装置
TW200619843A (en) 2004-10-20 2006-06-16 Sumitomo Bakelite Co Semiconductor wafer and semiconductor device
DE102004051277A1 (de) 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
JP2008520732A (ja) * 2004-11-23 2008-06-19 ワイス ゴナドトロピン放出ホルモン受容体アンタゴニスト
ATE422499T1 (de) * 2004-11-30 2009-02-15 Neurosearch As Neuartige diazabicyclische arylderivate als cholinerge liganden
SE527990C2 (sv) 2004-12-06 2006-08-01 Mora Of Sweden Ab Isborr
JP2008528700A (ja) 2005-02-03 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｐａｒモジュレーターとしての化合物および組成物
JP2006232707A (ja) 2005-02-23 2006-09-07 Japan Tobacco Inc 癌転移抑制剤
CA2604442A1 (fr) 2005-04-11 2006-10-19 Mingjun Huang Compositions pharmaceutiques et methodes d'inhibition de la replication du vhc
EP1871770A1 (fr) 2005-04-22 2008-01-02 Kalypsys, Inc. Inhibiteurs ortho-terphenyle de kinase p38 et procedes de traitement des troubles inflammatoires
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2006136829A2 (fr) 2005-06-21 2006-12-28 Astex Therapeutics Limited Composes pharmaceutiques
US20060288588A1 (en) 2005-06-22 2006-12-28 Frank Morabito Garden tool
WO2006138744A2 (fr) 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Derives d'heteroaryle utilises dans le traitement des virus
WO2006136637A2 (fr) * 2005-06-24 2006-12-28 Eloy Antonio Martinez Albal Implant dentaire a couronne rotative
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
CN100494167C (zh) 2005-08-02 2009-06-03 天津大学 抗乙肝病毒的叔胺氧化物及制备方法和制备药物的应用
GB0518237D0 (en) 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007052843A1 (fr) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited Compose amide heterocyclique et son utilisation
US7838676B2 (en) 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
JP2009519966A (ja) 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な６員ヘテロ環
EP1968568A4 (fr) * 2005-12-22 2011-04-13 Glaxosmithkline Llc INHIBITEURS D'ACTIVITE Akt
SI1962830T1 (sl) 2005-12-23 2013-07-31 Glaxosmithkline Llc Azaindolni inhibitorji kinaz Aurora
AR056882A1 (es) 2006-02-01 2007-10-31 Bayer Cropscience Sa Derivados del fungicida n- cicloalquil- bencil- amida
NZ595571A (en) 2006-02-28 2013-04-26 Helicon Therapeutics Inc Pyrazole compounds and uses thereof
JP2007277230A (ja) 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
EP2518063B1 (fr) 2006-12-21 2017-02-01 Sloan-Kettering Institute For Cancer Research Composés contenant des pyridazinones et furan
WO2008079371A1 (fr) 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulateurs du récepteur du c3a et leurs procédés d'utilisation
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
WO2008098105A1 (fr) 2007-02-07 2008-08-14 Smithkline Beecham Corporation Inhibiteurs de l'activité de akt
WO2008121685A1 (fr) 2007-03-28 2008-10-09 Smithkline Beecham Corporation Procédés d'utilisation pour inhibiteurs d'activité akt
EP2134175A4 (fr) 2007-03-29 2012-01-11 Glaxosmithkline Llc Inhibiteurs de l'activité de akt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0712397B1 (fr) * 1993-08-06 1999-04-21 Smithkline Beecham Plc Derives amides employes comme antagonistes du recepteur 5ht1d
WO2006136837A2 (fr) * 2005-06-23 2006-12-28 Astex Therapeutics Limited Composes pharmaceutiques

Also Published As

Publication number Publication date
IL200212A0 (en) 2010-04-29
EA018038B1 (ru) 2013-05-30
PL2117523T3 (pl) 2014-11-28
DOP2009000196A (es) 2009-10-31
JO3134B1 (ar) 2017-09-20
CA2678255A1 (fr) 2008-08-14
KR20090110866A (ko) 2009-10-22
JP5010038B2 (ja) 2012-08-29
AR066184A1 (es) 2009-08-05
MX2009008550A (es) 2009-11-09
US8410158B2 (en) 2013-04-02
AU2008213694A2 (en) 2010-06-24
US20090209607A1 (en) 2009-08-20
JP2010518110A (ja) 2010-05-27
BRPI0807146B8 (pt) 2021-05-25
IL200212A (en) 2015-07-30
KR20120130298A (ko) 2012-11-30
EP2117523B1 (fr) 2014-06-25
CN101646427B (zh) 2013-06-12
US20110071182A1 (en) 2011-03-24
WO2008098104A1 (fr) 2008-08-14
TWI507194B (zh) 2015-11-11
ZA200905363B (en) 2010-05-26
KR20140140570A (ko) 2014-12-09
PT2117523E (pt) 2014-09-29
US20160287561A1 (en) 2016-10-06
BRPI0807146A2 (pt) 2014-04-15
US20130231378A1 (en) 2013-09-05
HK1132676A1 (en) 2010-03-05
KR101537825B1 (ko) 2015-07-22
EP2117523A4 (fr) 2011-05-25
EA200970738A1 (ru) 2010-06-30
ES2501518T3 (es) 2014-10-02
CY1115535T1 (el) 2017-01-04
MA31167B1 (fr) 2010-02-01
CR10995A (es) 2009-10-16
TW201130490A (en) 2011-09-16
US20100267759A1 (en) 2010-10-21
US8273782B2 (en) 2012-09-25
US20100041726A1 (en) 2010-02-18
MY164480A (en) 2017-12-29
SG193678A1 (en) 2013-10-30
CN101646427A (zh) 2010-02-10
NZ579177A (en) 2012-01-12
PE20090058A1 (es) 2009-04-03
US20150152092A1 (en) 2015-06-04
UA102992C2 (en) 2013-09-10
UY30892A1 (es) 2008-09-02
EP2117523A1 (fr) 2009-11-18
KR101521002B1 (ko) 2015-05-19
CA2678255C (fr) 2014-06-03
JP2012167096A (ja) 2012-09-06
JP5511879B2 (ja) 2014-06-04
WO2008098104A8 (fr) 2009-07-30
US8946278B2 (en) 2015-02-03
TW200845964A (en) 2008-12-01
CO6220930A2 (es) 2010-11-19
AU2008213694A1 (en) 2008-08-14
AU2008213694B2 (en) 2013-07-04
JP4723677B2 (ja) 2011-07-13
JP2011126896A (ja) 2011-06-30
DK2117523T3 (da) 2014-09-08
HRP20140790T1 (hr) 2014-10-10
CL2008000348A1 (es) 2008-08-18
BRPI0807146B1 (pt) 2020-05-26
MX367398B (es) 2019-08-20
SI2117523T1 (sl) 2014-10-30

Similar Documents

Publication Publication Date Title
TWI381836B (zh) Ａｋｔ活性抑制劑
JP5363997B2 (ja) Ａｋｔ活性の阻害剤
JP2009521504A (ja) Ａｋｔ活性阻害剤
US20070185152A1 (en) Inhibitors of akt activity
JP2010522770A (ja) Ａｋｔ活性の阻害物質
WO2010093885A1 (fr) Inhibiteurs de l'activité d'akt